Palvella Therapeutics (PVLA) Consolidated Net Income: 2013-2024
Historic Consolidated Net Income for Palvella Therapeutics (PVLA) over the last 11 years, with Dec 2024 value amounting to -$4.0 million.
- Palvella Therapeutics' Consolidated Net Income fell 128.55% to -$4.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$17.4 million, marking a year-over-year decrease of 74.03%. This contributed to the annual value of -$17.4 million for FY2024, which is 193.27% down from last year.
- According to the latest figures from Q4 2024, Palvella Therapeutics' Consolidated Net Income is -$4.0 million, which was up 41.68% from -$6.8 million recorded in Q3 2024.
- Over the past 5 years, Palvella Therapeutics' Consolidated Net Income peaked at $13.8 million during Q4 2023, and registered a low of -$19.0 million during Q3 2021.
- For the 3-year period, Palvella Therapeutics' Consolidated Net Income averaged around -$5.9 million, with its median value being -$7.1 million (2022).
- Per our database at Business Quant, Palvella Therapeutics' Consolidated Net Income tumbled by 1,508.69% in 2020 and then spiked by 223.93% in 2023.
- Over the past 5 years, Palvella Therapeutics' Consolidated Net Income (Quarterly) stood at -$12.4 million in 2020, then rose by 11.27% to -$11.0 million in 2021, then dropped by 1.48% to -$11.2 million in 2022, then skyrocketed by 223.93% to $13.8 million in 2023, then plummeted by 128.55% to -$4.0 million in 2024.
- Its Consolidated Net Income stands at -$4.0 million for Q4 2024, versus -$6.8 million for Q3 2024 and -$4.2 million for Q2 2024.